MURANO Study Explores Potential for Venetoclax-Rituximab Combination Therapy in Relapsed/Refractory CLL

Conference Correspondent —December 17, 2018


ASH 2018

Researchers continue to focus on novel combination approaches in the treatment of chronic lymphocytic leukemia (CLL). In the phase 3 MURANO study, the efficacy and safety of venetoclax in combination with rituximab (VenR) in relapsed/refractory (R/R) CLL was evaluated as fixed-duration treatment compared with standard bendamustine + rituximab (BR). An initial analysis established a superior progression-free survival (PFS) of VenR over BR at median follow-up of 23.8 months (Seymour JF, et al. N Engl J Med. 2018). Here, researchers present longer-term outcome data with a median follow-up of 36 months.

Patients were randomized to receive 6 cycles of VenR followed by venetoclax 400 mg once daily for a maximum of 2 years, or 6 cycles of BR. In total, 389 patients were enrolled in the VenR (n = 194) and BR (n = 195) arms. In the VenR arm, 174 (90%) completed the VenR combination phase and 130 (67%) had completed 2 years of venetoclax treatment. For BR, 154 (79%) had completed 6 cycles.

With a median time of 9.9 months off venetoclax after 2 years of treatment, PFS with VenR remained superior to BR. Three-year PFS estimates were 71.4% for VenR versus 15.2% for BR, and 3-year overall survival estimates were 87.9% versus 79.5%, respectively. The treatment effect with VenR was consistent across subgroups, including age, number of prior regimens, and mutational status.

In terms of safety, the VenR regimen was well-tolerated, with no new safety signals. Notable grade 3/4 adverse events in the VenR arm (≥10%) included neutropenia (58.8%) and anemia (10.8%).

Researchers concluded that this study demonstrates clinically meaningful benefit of the VenR regimen in all patients with R/R CLL, with no new safety signals present.

Seymour JF, et al. ASH 2018. Abstract 184.

Related Articles
Improved MRD Response Rates with Ibrutinib and Obinutuzumab in Patients with CLL
Conference Correspondent
New data suggest that adding obinutuzumab to ibrutinib in patients with chronic lymphocytic leukemia (CLL) may be effective at improving minimal residual disease (MRD) response rates, especially in patients with low tumor burden after prior ibrutinib therapy.
Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (iFCG) for First-Line Treatment of Patients with CLL with Mutated IGHV
Conference Correspondent
The combination of ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab achieved a high rate of undetectable minimal residual disease in previously untreated patients with IGHV-mutated chronic lymphocytic leukemia (CLL).
Ibrutinib Alone or in Combination with Rituximab Produces Superior Progression-Free Survival Compared with Bendamustine plus Rituximab in Untreated Older Patients with CLL
Conference Correspondent
The ALLIANCE study showed that ibrutinib produces superior progression-free survival to standard chemoimmunotherapy in older patients with chronic lymphocytic leukemia (CLL).
Last modified: December 17, 2018

Subscribe to the Journal of Oncology Navigation & Survivorship®

To sign up for our print publication or e-newsletter, please enter your contact information below.

  • First Name *
    Last Name *
  • Please enter your mailing address.

    Address Line 2
    Zip Code